Top Management Commitment

Message from the President

Promoting Sustainability Management to Achieve Sustained Growth

Sumitomo Pharma Group defines the practice of its Mission, "To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide," that contributes to the realization of a sustainable society and leads to the sustained enhancement of its corporate value as "Sustainability Management."

In order to promote Sustainability Management, it is important to integrate diverse and changing issues and needs of society into business. We are committed to addressing and resolving health-related issues, which we consider as our primary social issues, by utilizing the strengths of our Group. The number of people suffering from non-communicable diseases is increasing on the background of global population growth and other factors, and medical needs for psychiatric and neurological disorders and cancer are expanding as aging of the population progresses.
I believe that the Group has a responsibility to continuously create innovative solutions to these health issues. We would like to contribute to the building of a healthy and vibrant society by continuing to provide value that only the Group can offer, not only to support the well-being of patients, but also to assist their families and caregivers. We have positioned “Development of innovative products and healthcare solutions” as most important among our Material Issues, which we identify based on the two axes of “expectations from society” and “impact on corporate value enhancement.”

On the other hand, in order to deliver value as soon as possible, we recognize the immediate improvement of our Group's financial situation as our top priority at present and will exert maximum effort with a sense of urgency. We are working on a wide range of new products, from small molecule drugs based on our cumulative experience and expertise to regenerative medicine & cell therapy utilizing technologies acquired through our pioneering efforts. We aim to establish a unique global position by bringing innovation to conventional treatment systems through a variety of approaches and contributing to all phases of the patient journey, from disease prevention to return to society.
Innovation is necessary to generate these advanced solutions, and the source of this innovation is human resources (HR). “Instilling corporate culture and implementing HR strategies” is one of priority issues identified in the MTBP2027, and we will work to build up an HR portfolio, empower diverse HR, and penetrate our philosophy globally to maintain a sense of unity and high engagement within the Group. Through these efforts, we will achieve individual and business growth and continuously provide value to society.

We are committed to creating innovative products and healthcare solutions that will best contribute to Goal 3 (good health and well-being) of the United Nations Sustainable Development Goals (SDGs). We are also committed to environmental initiatives such as those to tackle climate change, which humanity urgently needs to address; respect for human rights of our stakeholders including employees; and promotion of compliance to further enhance corporate ethics as a company in the life sciences industry. Thus, while focusing on Goal 3, we will continue to help society be more sustainable and strive for the sustained growth of the Group by further strengthening our efforts to achieve goals beyond Goal 3 throughout our entire business.

Finally, on behalf of Sumitomo Pharma, I would like to express my sincere gratitude to all stakeholders for your interest in the Company and ask for your continued understanding and support.